Ayala Pharmaceuticals: Fiscal Q4 Earnings Snapshot
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) and Advaxis, Inc. is fair to Ayala shareholders. Upon completion of the...
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Ayala Pharmaceuticals, Inc. (AYLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
A small %Biotech company saw its shares trading higher during Tuesday’s session after the company announced its second quarter financial results for 2022. Some financial highlights from the press release...
Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 1.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?